Kemnay Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Kemnay Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.08K	Buy	42 +2	+5%	+$297	﹤0.01%	1120
2026 Q1	$5.27K	Buy	+40	New	+$5.31K	﹤0.01%	1162
2020 Q3	–	Sell	-4,292	Closed	-$524K	–	93
2020 Q2	$524K	Sell	4,292 -5,676	-57%	-$627K	0.08%	62
2020 Q1	$863K	Sell	9,968 -8,172	-45%	-$800K	0.24%	33
2019 Q4	$1.95M	Buy	+18,140	New	+$1.9M	0.48%	35

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kemnay Advisory Services's NBIX Position: Q2 2026 in Review

Kemnay Advisory Services increased its Neurocrine Biosciences (NBIX) stake by 5% in Q2 2026, buying an estimated $297 and bringing the position to 42 shares worth $7.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1120.

Kemnay Advisory Services first reported a position in NBIX in Q4 2019 and has held it in 5 quarters since. The position peaked at $1.95M in Q4 2019. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Kemnay Advisory Services held 42 shares of Neurocrine Biosciences worth $7.08K as of Q2 2026.
Kemnay Advisory Services bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
Neurocrine Biosciences made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #1120 holding.
Kemnay Advisory Services first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 5 quarters since.
Kemnay Advisory Services's Neurocrine Biosciences position peaked at $1.95M in Q4 2019.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.